1. The following databases were searched from inception to October 2015 using the keyword "MiniMed 640G": Ovid MEDLINE(R) In‑Process & Other Non‑Indexed Citations and Ovid MEDLINE(R); Embase (via OVID); Cochrane Library; CAB Abstracts; Web of Science's Science Citation Index.
2. The internet was searched using the above keyword.
3. ClinicalTrials.gov, WHO ICTRP, and Current Controlled Trials were also searched for ongoing trials.
4. Information provided by the manufacturer in supporting this briefing was checked to identify any further information.
5. The manufacturer's website was thoroughly investigated.
6. Information provided by the manufacturer was thoroughly checked for relevant studies.
The inclusion criteria were as follows:
Population: adults and children with type 1 diabetes who currently use or may benefit from using an insulin pump.
Intervention: MiniMed 640G insulin pump.
Comparator: any integrated or non‑integrated systems for the monitoring and delivery of insulin including pumps, continuous glucose monitoring, self‑monitoring and subcutaneous injection.
number and frequency of hypoglycaemic events
unplanned hospital visits
variability in blood glucose levels
glucose control as measured by HbA1c (glycated haemoglobin)
Study type: published clinical studies. Proof‑of‑concept, bench‑top or basic science studies were excluded. Non‑English language studies were excluded.